Web2X One Step RT-PCR Buffer III 10 μl 25 μl 1X TaKaRa Ex Taq HS (5 U/ μl) 0.4 μl 1 μl PrimeScript RT enzyme Mix II 0.4 μl 1 μl PCR Forward Primer (10 μM) 0.4 μl 1 μl 0.2 μM*1 PCR Reverse Primer (10 μM) 0.4 μl 1 μl 0.2 μM*1 Probe 0.8 μl 2 μl*2 ROX Reference Dye or Dye II (50X)*3 0.4 μl 1 μl total RNA 2 μl 4 μl*4 WebBecause this real-time RT-PCR kit is powered by PrimeScript Reverse Transcriptase, it enables full-length cDNA synthesis for real-time RT-PCR (qPCR) in just 15 minutes. This …
IJMS Free Full-Text Identifying Differentially Expressed Genes in ...
WebPrimeScript™ Reverse Transcriptase. 卓越した伸長能をもつ逆転写酵素のニュースタンダード. Reverse Transcriptase XL (AMV) for RT-PCR Kit. RNA PCR Kit のコンポーネント. TaKaRa RNA PCR™ Kit (AMV) Ver.3.0. TaKaRa Ex Taq ® HSとAMV RTaseを用いた2ステップRT-PCR用キット. PrimeScript™ II Reverse ... WebThis kit is designed for two-step RT-PCR and should be used with one of Takara Bio's qPCR premixes such as TB Green Premix Ex Taq II ... (Cat. # RR390A). Over 3,700 … potential risks of infection in healthcare
Fast reverse transcription from mouse blood samples …
Web4 lug 2024 · As a reaction solution (50 μL), 10 × RT buffer (5 μL), 100 mM dNTP Mix (2 μL), 10 × RT Random Primers (5 μL), 50 U/μL MultiScribe™ Reverse Transcriptase (Thermo Fisher Scientific Inc.) (2.5 μL), 40 U/μL Recombinant RNase Inhibitor (1.25 μL), RT-PCR Grade Water and total RNA were mixed into a PCR tube, wherein the total volume was ... Web6 giu 2024 · The present invention provides a method for stably preserving an oligonucleotide-containing solution by adding a nucleic acid-binding protein to said oligonucleotide-containing solution in advance. Type: Grant. Filed: June 6, 2024. Date of Patent: February 7, 2024. Assignee: TAKARA BIO INC. Web10 lug 2024 · The complementary strand was synthesized by moloney murine leukemia virus (MMLV) reverse transcriptase (Takara Bio, Dalian, China). cDNA was ligated with three types of attB1 adapters to generate three possible reading frames, which were then introduced to the prey vector pPR3-N-R1R2. potential risks of mrna vaccine